| COVID-19 |
1 |
1 |
| Heart Failure (HF) |
0 |
0.98 |
| Cardiovascular Imaging |
0 |
0.68 |
| Heart |
0 |
0.65 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.49 |
| Hyperbaric Oxygen Therapy |
0 |
0.99 |
| Biologic Therapy |
0 |
0.24 |
| Genomic Medicine |
0 |
0.24 |
| Precision Medicine |
0 |
0.24 |
| Echocardiography |
0 |
0.16 |
| Europe |
0 |
0.16 |
| New York |
0 |
0.16 |
| Cerebrovascular Accident |
0 |
0.14 |
| Diabetic Foot |
0 |
0.14 |
| Wound Management |
0 |
0.14 |
| Cognitive Impairment |
0 |
0.12 |
| Diabetic Foot Ulcer |
0 |
0.12 |
| Diabetic Microvascular Complications |
0 |
0.11 |
| Adverse Effects |
0 |
0.08 |
| Biomarker |
0 |
0.08 |
| Decompression Sickness |
0 |
0.08 |
| Ejection Fraction |
0 |
0.08 |
| Impairment |
0 |
0.08 |
| Mild Cognitive Impairment |
0 |
0.08 |
| Oxygen Therapy |
0 |
0.08 |
| Pandemic |
0 |
0.08 |
| Patient Safety |
0 |
0.08 |
| Pedal |
0 |
0.08 |
| Quality of Life |
0 |
0.08 |
| Surgery |
0 |
0.08 |
| Type 2 Diabetes Mellitus |
0 |
0.08 |
| Wound |
0 |
0.08 |